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Abstract: Gestational diabetes mellitus (GDM) is a major public health problem and a threat to
maternal and child health. There is a lack of integrated and systematically synthesized knowledge
about the prevalence GDM in Norway. Therefore, this systemic review aimed to present the best
available peer-reviewed published evidence from the past 20 years about the prevalence of GDM in
Norway. A comprehensive literature search was performed on online databases consisting of PubMed
(including Medline), Web of Science, and Scopus to retrieve original research articles published on
the prevalence of GDM up to August 2020. Also, databases of Norart and SveMed+ in the Norwegian
language were searched to enhance the search coverage. Data were extracted using a standardized
protocol and data collection form and were presented narratively. A total of 11 studies were selected
to include for data analysis and synthesis with the total sample size of 2,314,191 pregnant women.
The studies included heterogenous populations and mostly reported the prevalence of GDM in
healthy mothers with singleton pregnancies. The prevalence of GDM in population registered-
based studies in Norway was reported to be lower than 2%, using the World Health Organization
(WHO) 1999 criteria. However, studies on high-risk populations such as the non-European ethnicity
reported prevalence rates ranging from 8% to 15%. Given the evidence from available literature
that reported trends in the prevalence of GDM, an increase in the prevalence of GDM across most
racial/ethnic groups studied in Norway was observed. Overall, the prevalence of GDM in the low
risk population of Norway is fairly low, but the available literature supports the perspective that the
prevalence of GDM has shown an increasing trend in recent decades. This finding is very important
for health service planning and evaluation, policy development, and research in Norway. Large-scale
prospective studies, using the national data, are warranted to provide firm evidence over coming
years. Our review findings can help policy makers devise appropriate strategies for improving
women’s reproductive health.
Keywords: gestational diabetes mellitus (GDM); health care; Norway; public health; prevalence;
reproductive health; systemic review
1. Introduction
Gestational diabetes mellitus (GDM) is considered a major pregnancy complication [1].
It has been defined as glucose intolerance in the second or third trimester of pregnancy
in women who have had not clearly overt diabetes prior to gestation [2]. This is one
of the most common endocrinopathies affecting 4–12% of all pregnancies. However, its
prevalence is raised depending on diagnostic criteria and the presence of different risk
factors such as maternal age and body mass index (BMI); prevalence of overt diabetes;
population ethnicity; genetic, social, and environmental factors [3–6].
The etiology of GDM is multifactorial and has not been completely understood. In
most patients with GDM, gestational hyperglycemia is the result of impaired glucose
tolerance due to pancreatic β-cell dysfunction and post-receptor defects in the insulin
signaling cascade, as the background of chronic insulin resistance [7,8]. It is followed by
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progressive insulin resistance due to the increased placental production of diabetogenic
hormones including estrogen, progesterone, and human placental lactogen during the
second trimester of pregnancy [9,10]. However, GDM carries a serious risk of feto-maternal,
neonatal mortality and morbidity [11], and the lifelong risk of obesity, type 2 diabetes
mellitus and cardiovascular diseases in the mother and child later in life [12–15].
During the last 20 years, the prevalence of GDM has increased worldwide and it
is expected to continue to rise along with an increase in advanced maternal age, pre-
conception obesity and impaired glucose tolerance among women [16,17]. Moreover, the
use of the universal screening strategy and the more stringent diagnostic criteria for GDM
lead to a higher prevalence of GDM among pregnant women and potentially increase the
costs of health care [18].
Nordic countries as well have shown a similar trend in increasing the aforementioned
risk factors [19,20]. Specifically in Norway, the mean of maternal age at first birth in the
recent two decades has been more than 25 years with an increasing trend from 27.3 years
in 2000 to 29.8 years in 2019 with the most pronounced in the recent decade [21], which can
influence the prevalence of GDM and other related health outcomes. In addition, it has
been reported that 4.7% of the Norwegian population have a diabetes diagnosis. Although
this is fairly low compared to the global scale, it has shown an increasing trend as well [22].
According to the Norwegian guidelines, the target-based screening approach has
been recommended for high-risk pregnant women including those with a maternal age
older than 25 years, previous history of GDM, macrosomia greater than 4500 g, shoulder
dystocia, first relative’s overt diabetes history, Asian and African ethnicity and those
with a BMI more than 30 kg/m2 [23]. In this respect, pregnant women are set to have
two screening phases as follows: (i) measurement of Hb A1C at the first trimester of
pregnancy before the 16 weeks of gestation for high risk pregnant women to find any
kind of undiagnosed hyperglycemia, and (ii) oral glucose tolerance test (OGTT) with 75 g
glucose at the 24–28 weeks of gestation for high-risk pregnant women who have the normal
glycemia condition at the first-trimester screening.
For the last two decades in Norway, GDM has been defined based on the WHO-1999
criteria as follows: fasting blood glucose level (FBS) ≥ 7.0 mmol/L and/or OGTT 75 g
2 h level of blood glucose (BS-2h) ≥ 7.8 mmol/L [23]. In 2017, the Norwegian institute
of public health revised the GDM definition and suggested the lower diagnostic glucose
threshold compared to the previously used criteria [24]. According to the new guideline,
GDM has been defined as the FBS level between 5.3 and 6.9 mmol/l and/or a BS-2h level
between 9.0 and 11.0 mmol/l after a 75 g OGTT. The latest national report in 2019 estimated
that the prevalence of GDM in Norway ranges between 3% and 8% using the WHO 1999
criteria and 10% or maybe even more based on the new criteria [24]. In addition, some
studies indicate concerns about the underestimation of the prevalence of GDM in the
general population [25,26]. Therefore, the aim of this systemic review was to present the
best available peer-reviewed published evidence about the prevalence of GDM in Norway
in order to provide an up-to-date overview of the current knowledge about GDM.
2. Materials and Methods
2.1. Design
A systematic review of national and international literature was conducted that was
informed by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) [27].
2.2. Eligibility Criteria
Appropriate studies for inclusion to data analysis and knowledge synthesis were orig-
inal research studies, focused on the prevalence of GDM in Norway, published in scientific
peer-reviewed journals and in English and Norwegian language. Therefore, non-original
studies including reviews, commentaries, editorials, letters, conference proceedings, case
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reports that did not provide accurate and clear data were excluded. In addition, studies
that reported on similar study populations at a similar point in time were excluded.
2.3. Search Strategy
A comprehensive literature search was conducted on online databases such as PubMed
(including Medline), Web of Science and Scopus to retrieve all relevant articles published up
to August 2020. Also, the databases of Norart and SveMed+ in Norwegian language were
searched to enhance the search coverage. Further, a manual search in the references list of
selected studies and other relevant reviews was performed to maximize the identification
of eligible studies.
The following keywords, alone or in combination, using the Boolean method, were
used to carry out the search: (gestational diabetes OR gestational diabetes mellitus OR
GDM OR pregnancy induced diabetes OR gestational hyperglycemia OR gestational glu-
cose intolerance) AND (incidence OR prevalence OR epidemiology) AND (Norway OR
Norwegian OR Scandinavia OR Scandinavian). Support with the search process was
achieved from an expert librarian.
2.4. Study Selection and Data Extraction
The screening of titles, abstracts and full text of retrieved articles based on the eli-
gibility criteria was performed independently by the authors. For each eligible study, a
predetermined data extraction form was used to collect the following data: author’s name,
journal, publication year, study design, data resources, sample size, population charac-
teristics including age and BMI, GDM screening strategy, GDM criteria and laboratory
values of blood sugar tests, study quality assessment and outcome measurement including
the number and prevalence of GDM. Discussions were held by the authors to check the
search process and resolve disagreements on the inclusion of selected studies. Given
heterogeneities in the methods, objectives, and results of the selected studies, they did not
lend themselves to meta-analysis. Therefore, the review results were described narratively.
2.5. Quality Assessment and Risk of Bias
The quality of the studies was critically appraised in terms of methodological structure
and presentation of results. Two members of the research team who were blinded to study
author, journal name and institution evaluated the quality of the studies independently.
The quality of observational studies was assessed using the modification of the Newcastle–
Ottawa Quality Assessment Scale for Non-Randomized Studies (NRS) [28] regarding
selection, comparability and outcomes. Studies with scores above 6 were considered high
quality, 4–6 moderate quality, and less than 4 low quality. The risk of bias in observational
studies was assessed using the Risk of Bias in Non-Randomized Studies (ROBINS) tool.
Five domains related to risk of bias were assessed in each cross-sectional study including:
bias in the assessment of exposure, development of the outcome of interest in case and
controls, bias in the selection of cases, selection of controls, and control of prognostic
variables. In addition, seven domains related to risk of bias were assessed including bias in
the selection of exposed and non-exposed cohort, assessment of exposure, presence of the
outcome of interest at the start of the study, the control of prognostic variables, assessment
of the presence or absence of prognostic factors, assessment of outcome, and adequacy
regarding the follow up of cohorts. Authors’ judgments were categorized as ‘low risk’,
‘high risk’, and ‘unclear risk’.
3. Results
3.1. Search Results and Study Selections
The search strategy yielded 106 potentially relevant articles, of which 32 articles
were identified for further full-text assessment. Finally, 11 studies [26,29–38] consisting
of data from 2,314,191 pregnant women were selected for inclusion to the data analysis
(Figure 1). The full-text appraisal of the studies did not lead to the exclusion of any study
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as they all had the acceptable quality in terms of the research structure and relevance to
the review aim. Therefore, all selected studies were included to the data analysis and
knowledge synthesis.
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3.2. General Characteristics of the Selected Studies
The characteristics of the selected studies assessing the prevalence of GDM in Norway
were presented in Table 1. Among the studies included, 9 (81.8%) used a population-based
design [26,30,32–38]. A total of 6 (54.5%) studies used the national data of Medical Birth
Registry of Norway [30,32–34,37,38] and other studies used data from local hospitals and
public health clinics in Oslo, the capital city [26,29,35], Trondheim and Stavanger [31], and
Nordland and Tromsø [36]. All studies used the national criteria for the diagnosis of GDM.
In addition to national definition, two (18.1%) studies used the International Association of
Diabetes and Pregnancy Study Group (IADPSG) or Modified IADPSG criteria [26,31], one
(9%) the WHO-2013 criteria [35] and one (9%) the 2017 revised national criteria [35] for the
diagnosis of GDM. The studies’ population was heterogenous, but they mostly reported
the prevalence of GDM in healthy mothers with singleton pregnancies lasting more than
22 weeks of gestation.
3.3. Prevalence of Gestational Diabetes Mellitus (GDM) in Norway
Some regional and registered studies were conducted in the different parts of Norway.
The reported range of GDM, according to the selected studies, varied widely with a range
as low as 0.7% [37] to as high as 31.5% [26], mostly due to various GDM diagnostic criteria,
ethnicity of participants, data sources and the population-based design of studies. In this
respect, using the national criteria, the reported prevalence of GDM varied widely, ranging
from 0.9% to 13.4% [26,29,31–34,36,38]. However, the use of the strictest criteria of IADPGS
and WHO 2013 sharply increased the prevalence of GDM from 7.4% to 31.5% [26,31,35].
On the other hand, use of the 2017-revised national criteria, it was estimated that 9.2% of
pregnant women had GDM [35].
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Table 1. The characteristics of the selected studies for data analysis and knowledge synthesis.
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Table 1. Cont.
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University Hospital 2002–2008
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1. 2004–2006: 72 (1)
2. 2007–2009: NM
3. 2010–2012: NM
4. 2013–2015: 356 (4)
5. Total: 782 (2.2)
6. non-European ethnicity: 111
(14.7)
GDM: gestational diabetes; FBS: fasting blood sugar; BS-2h: blood sugar 2 h; NM: Not Mentioned; WHO: World Health Organization; OGTT: oral glucose tolerance test; IADPSG: International Association of
Diabetes and Pregnancy Study Group.
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Among these population-based studies conducted in Norway, the prevalence of GDM
was approximately 13% in one study [26], and 1–2% in other studies [30,32–34,36]. The
prevalence of GDM in population registered-based studies in Norway is lower than 2%,
using the World Health Organization (WHO) 1999 criteria [32–34,37,38]. While studies
in high-risk populations, such as the non-European ethnicity, reported prevalence rates
ranging from 8% to 15% [26,36,38]. Jenum, et al. (2012) in a population-based study
reported that GDM was more prevalent in non-Western Europeans minority groups from
south, east and middle east Asia, eastern Europe, Somalia, sub-Saharan Africa and south
America than the Western European pregnant women, (15% vs. 11%) using the national
criteria and (37% vs. 24%) using the modified IADPSG definition for GDM, respectively [26].
Leeves, et al. (2019) in a hospital-based study of two northern cities of Norway indicated
that pregnant women of non-European ethnicity had a greater risk of developing GDM
compared to the European ethnicity pregnant women as 14.7% vs. 2.2%, respectively [36].
In some selected studies, surveys were repeated over time or different surveys were
conducted at different time points, allowing the estimation of changes in the prevalence of
GDM over time. Although no published trend study was retrieved, the reported prevalence
of GDM tended to be higher in recent years than before. In this respect, using the national
criteria and database, Engeland et al. (2011) reported that the prevalence of GDM in Norway
rose uniformly across different population groups between 2004 to 2008 from 0.8% to 1.2%,
respectively [30]. Furthermore, Leeves, et al. (2019) reported that it increased from 1% in
2004 to 4% in 2015 [36]. A summary of the prevalence of GDM in various population- and
non-population -based studies using the national criteria has been presented in Figure 2.
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3.4. Quality Assessment and Risk of Bias Results
Details of the quality assessment of studies incl ed ar presented in t e supple-
mentary tables and figures. Accordingly, 90% of the studies were classified as high qual-
ity [26,29,30,32–38], and 9% as moderate [31], and n study had low quality. Over ll, most
of the studies were judged as having low risk of bias for the evaluated domains.
Cohort studies had a low risk of bias for the assessment of exposure, presence of
the outcome of interest at the start of the study, outcome assessment, assessment of the
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presence or absence of prognostic factors, and adequacy of follow up of cohorts; however,
one third of them had a high risk of bias in controlling prognostic variables and 14% of
them had a probable risk of bias in the selection of exposed and non-exposed cohorts
(Table S1, Figure S1).
All cross-sectional studies had a low risk of bias in the assessment of exposure and
development of outcome of interest, but approximately one third of them had a high risk
of selection of cases and controls, and control of prognostic variables (Table S2, Figure S2).
4. Discussion
This review aimed to collect data from the literature systematically and synthesize
knowledge about the prevalence of GDM in Norway. The findings of 11 studies were
summarized in this review, suggesting that the prevalence of GDM in population registered-
based studies in Norway was lower than 2%, using the WHO 1999-criteria. On the other
hand, studies on high-risk populations such as those of non-European ethnicity reported a
prevalence rate ranging from 8% to 15%. It should be noted that these studies included
heterogenous populations and mostly reported the prevalence of GDM in healthy mothers
with singleton pregnancies. Our findings support the perspective that the prevalence of
GDM have had an increasing trend in the recent decades. However, drawing a robust
conclusion about the prevalence of GDM and its trend in Norway needs further population-
based research.
GDM is one of the most important endocrinopathies during pregnancy [1]. The label
of GDM brings with itself an intervention package consisting of glucose monitoring; extra
clinic visits; more obstetric monitoring with greater likelihood of intervention; a label of
high risk for developing metabolic disturbances and diabetes in the mother [39]. Therefore,
it is of great public health significance to understand the feature of GDM with a national
scope in each country.
Despite ethnic differences and variations in diagnostic criteria for GDM between
countries, an increase in the prevalence of GDM and GDM-related risk factors has been
observed in different healthcare settings. Therefore, it leaves no doubt that GDM has
become a public health concern for many societies including developed western countries
with a lower prevalence of GDM [40–42] with negative consequences for substantial short-
and long-term adverse health outcomes for the mother and offspring [43,44]. Nevertheless,
Nordic countries including Norway are known for having a relatively low prevalence of
GDM on the global scale, which can be attributed to ethnicity, lower prevalence type 2
diabetes and obesity, and also a higher socioeconomic level compared to other nations
across the globe [19,20].
According to the national report in Norway, the prevalence of GDM was 3–8% [24].
This estimation is higher than the estimation reported in other studies based on this
database [30,32–34], but it is lower than the report of the recent published population-
based non-registry study [26]. It can be assumed that the high percentage of disagreement
between studies evaluating the prevalence of GDM can be explained by their method-
ological heterogeneities in terms of the study design, participants’ inclusion and exclusion
criteria and parity, which explain the conflicting findings in our review. Moreover, the
exact year of the conducted research may constitute an additional factor influencing the
heterogeneity of the measured prevalence.
Our review showed an increasing trend of the prevalence of GDM during recent years
in Norway. Similarly, other Nordic countries such as Denmark and Sweden [19,20] have
reported the growing prevalence of GDM. However, increasing maternal age, along with
the increasing rate of other risk factors such as diabetes, obesity and the growing number
of women born outside of Scandinavia can be the underlying causes of the increasing rate
of GDM [26,36,45,46].
According to our review, the prevalence of GDM among non-European pregnant
women, particularly from the Middle East, south Asia and India was higher than that of
the Western European population [47,48]. Norway is one of the European countries with
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in-migration from other ethnicities with a higher risk of GDM during recent years, which
may potentially have affected the total prevalence of GDM in the general population. How-
ever, one of the most important factors influencing the prevalence of GDM is diagnostic
criteria [2]. The Norwegian national GDM diagnostic criteria has been revised in 2017,
which has recommended a lower glucose threshold for OGTT-75 g glucose. Up until now,
only one study has assessed the prevalence of GDM based on the new criteria and has
reported that 9.2% of pregnancies among low-risk women of Scandinavian heritage are
affected by GDM [35].
The strength of this review lies in its concentration on scientific peer-reviewed pub-
lished studies from Norway in both English and Norwegian language that have estimated
GDM based on the recruitment of the large number of pregnant women. Also, the authors
of this review sought to use a broad search strategy based on their previous experiences
with the research topic and the process of systematic review as well as through the applica-
tion of various general and specialized key words to identify all potentially eligible studies
for inclusion. Furthermore, time and date restrictions were avoided to prevent selection
bias. In addition, most of the included studies had high quality with low risk of bias, which
led to a reliable conclusion of the selected studies’ findings. However, the available data
were too diverse to yield a very concrete summary estimate of the prevalence of GDM. This
was mainly due to the heterogeneity between inclusion criteria of the studies’ population
that limited the comparability across the selected studies and hindered performing a meta-
analysis. Moreover, since the new criteria for diagnosing GDM were established in 2017,
there has not been a sufficient number of studies to assess the prevalence of GDM based on
the new criteria.
5. Conclusions
Several aspects remain to be elucidated in order to completely clarify the prevalence of
GDM and its trend in Norway. The overall prevalence of GDM in the low-risk population
of Norway was reported low, but the evidence from the available literature supported the
perspective that the prevalence of GDM has had an increasing trend in recent decades.
Large-scale prospective cohort studies using the national registries data and also using new
criteria are warranted to provide more robust evidence regarding the prevalence of GDM
and its trend over the years, and assess the contribution of potential confounders including
maternal age, BMI, and ethnicity. Our review findings can be used by policy makers in
Norway and in other countries with a similar trend of GDM for devising appropriate health
care strategies for improving women’s reproductive health.
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Table S1. Quality assessment of the selected studies using the Newcastle–Ottawa Quality Assessment Scale for cohort studies. 
Author, Year 
Selection (Maximum Four *) 
Comparability 
(Maximum Two *) 




of The Exposed 
Cohort * 




of Exposure * 
No Outcome of 
Interest at Start 
of The Study * 
Controlled for 
confounders: 
A: Age and/or BMI * 
B: others * 
Assessment of outcome (maximum 
one *) 
A: Doctor’s Diagnosis OR 
Objective Measurements * 
B: Parent/Self-Reported Doctor’s 
Diagnosis OR Use of Medication * 
Follow-Up 
Long Enough 
for Outcomes * 
Adequacy of 
Follow Up of 
Cohorts * 
Clausen et al. (2006)   * * ** * * * 7 * 
Engeland et al. (2011) * * * * * * * * 8 * 
Jenum et al. (2012) * * * * ** * * * 9 * 
Leirgul et al. (2016) * * * * ** * * * 9 * 
Sorbye et al. (2017 * * * * ** * * * 9 * 
Lekva et al. (2018) * * * * * * * * 8 * 
Leeves et al. (2019) * * * * ** * * * 9 * 
BMI: body mass index. 
Table S2. Quality assessment of the selected studies using the Newcastle–Ottawa Quality Assessment Scale for cross-sectional studies. 
Author, Year 
Selection (Maximum Four *) 
Comparability (Maximum 
Two *) 
Outcome (Maximum Three *) 
Total Scores 
Representativeness 




Ascertainment of The 
Exposure (Risk Factor) * 
Controlled for confounders: 
A: Age and/or BMI * 
B: others * 
Assessment of The Outcome 
(maximum two *) 
a) Independent Blind Assessment ** 
b) Record Linkage ** 
c) Self Report * 
Statistical 
Test * 
Bakken et al. (2017) * *  * ** ** * 8 * 
Helseth et al. (2014)    *  ** * 4 * 
Sørbye et al. (2014) * *  * ** ** * 8 * 
Strøm-Roum et al. (2016) *   * ** ** * 7 * 




















Figure S2. Risk of bias in cross-sectional studies. 
